Remibrutinib for Chronic Itch

This trial tests a new treatment called remibrutinib for individuals with severe chronic itch of unknown origin. Researchers aim to evaluate the treatment's effectiveness and safety for those experiencing this itch for at least four months, particularly if it affects multiple areas such as the trunk, arms, or legs. Participants must have a severe itch that hasn't improved with standard creams and may require stronger, whole-body treatment. Some participants will begin with a placebo and switch to remibrutinib after 24 weeks, while others will receive remibrutinib from the start. As a Phase 3 trial, this treatment represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking research.

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on dual anti-platelet therapy, you cannot participate in the trial.

Studies have shown that remibrutinib is safe with few side effects. Research indicates that this treatment effectively manages chronic itch, or pruritus. People generally tolerate it well, with few reports of negative reactions. Although more research is needed, current evidence suggests that remibrutinib does not cause major problems for users.¹²³⁴⁵

Most treatments for chronic itch focus on managing symptoms with antihistamines or corticosteroids. However, remibrutinib stands out because it targets a different pathway. It is a Bruton’s tyrosine kinase (BTK) inhibitor, which means it works by interfering with signals that lead to itch and inflammation. This new mechanism of action could offer relief for those who don't respond well to current treatments. Researchers are excited about remibrutinib because it has the potential to address the underlying causes of chronic itch rather than just alleviating the symptoms.

Research has shown that remibrutinib reduces symptoms of chronic spontaneous urticaria, a condition similar to chronic itching. Studies found that patients experienced significant improvements, such as less itching and fewer hives, as early as the first week of treatment. By Week 12, 70.9% of patients had their symptoms well under control. These benefits persisted, with some studies showing positive effects up to Week 52. In this trial, participants will either receive remibrutinib directly or start with a placebo followed by remibrutinib. This evidence suggests that remibrutinib may effectively reduce severe chronic itching symptoms for those considering this treatment.⁶⁷⁸⁹¹⁰